Vaccine Therapy Suppliers In North America

EnGen Bio is developing a therapy and vaccine to provide lifetime immunity to Type A flu. We´ve discovered influenza´s ¨Achille´s heel¨ Unlike conventional flu vaccines, which are generally hemagglutinin or whole-virus based, our vaccine targets a ...

SiO2 Materials Science is focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. In the pharma segment, we solve more than 30 problems including some of the most challenging related to drug stability, drug ...

Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, ...

Matica Biotechnology is a cell and gene therapy CDMO that is bringing together integrated GMP manufacturing platforms and innovative solutions resulting in speed to clinic without sacrificing quality. Our investments in advanced, single-use ...

GlycoBac has developed a sensitive assay for infectious Sf-rhabdovirus particles using our proprietary Sf-RVN cell line. GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and ...

Latham BioPharm Group (LBG) is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development ...

MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...

Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Jean-Simon Diallo at the Ottawa Hospital Research Institute. Dr. Diallo was investigating novel oncolytic viral therapies (OVTs) and recognized the need for VSEs to ...

iPSCs- a revolutionary discovery with untapped potential. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells ...